Eylea HD sales will reach 76% of the peak sales value of Eylea in 2031, GlobalData analysts forecast 

While Eylea HD will not completely reduce the sales losses associated with Eylea's patent cliff, it will significantly diminish the burden of profit loss experienced by the drug's maker, Regeneron.